PA
ALEX

PharVision Advisers’s Alexander & Baldwin ALEX Stock Holding History

PharVision Advisers’s Portfolio ALEX Stock Details ALEX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,400
Closed -$231K – 270
2025
Q1 		$231K Buy
13,400
+1,606
+14% +$28.4K 0.32% 155
2024
Q4 		$209K Buy
+11,794
New +$222K 0.18% 283

Other funds holding ALEX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PharVision Advisers's ALEX Position: Q2 2025 in Review

PharVision Advisers sold out of Alexander & Baldwin (ALEX) in Q2 2025, closing a stake of 13,400 shares — an estimated $231K sold.

PharVision Advisers first reported a position in ALEX in Q4 2024 and held it in 2 quarters. The position peaked at $231K in Q1 2025. 259 funds tracked by Wall St. Rank hold ALEX as of Q2 2025.

  • PharVision Advisers reported no remaining Alexander & Baldwin position as of Q2 2025 after selling out during the quarter.
  • PharVision Advisers sold 13,400 Alexander & Baldwin shares in Q2 2025, an estimated $231K.
  • PharVision Advisers first reported a position in Alexander & Baldwin in Q4 2024 and held it in 2 quarters.
  • PharVision Advisers's Alexander & Baldwin position peaked at $231K in Q1 2025.
  • 259 funds tracked by Wall St. Rank held Alexander & Baldwin as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.